Answers are grounded in this paper and cite their sources.
This review highlights immune checkpoint inhibitors' impact on survival in recurrent HNSCC, suggesting personalized approaches.
Head and neck squamous cell carcinoma (HNSCC) remains a significant public health burden, especially in India, where a majority present with advanced disease and poor prognosis. Recent advances in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have transformed the treatment landscape for recurrent/metastatic HNSCC. This comprehensive review outlines the immunobiological mechanisms underlying HNSCC, including tumor-induced immune evasion through the tumor microenvironment and checkpoint pathways such as programmed cell death protein-1/programmed death-ligand 1, cytotoxic T lymphocyte antigen-4, lymphocyte activation gene-3, T-cell immunoglobulin mucin-3, and T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif. Key clinical trials have established pembrolizumab and nivolumab as effective ICIs, offering superior survival and tolerability over traditional chemotherapy in both first- and second-line settings. Beyond ICIs, the article explores novel approaches including human papillomavirus-targeted vaccines, chimeric antigen receptor T-cell therapies, and combination regimens with epidermal growth factor receptor inhibitors or tyrosine kinase inhibitors. Despite these advancements, therapeutic resistance, immune-related adverse events, and financial toxicity remain key challenges. Future directions emphasize personalized immunotherapy guided by biomarkers and multiomic profiling, along with strategies such as low-dose ICI and bispecific antibodies. Immunotherapy is redefining the prognosis of advanced HNSCC, moving toward long-term disease control and potential chronic management.
No takes yet. Share an insight, caveat, or question.
Sunny et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: